Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review
Basic & Clinical Pharmacology & Toxicology · 2026-06 · 138 (6)
DOI: 10.1111/bcpt.70243 ↗Kurz gefasst
Scoping Review in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 10.05.2026. Verfasst von Lasse Alajärvi und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Environment, Drug Costs, Reimbursement Mechanisms. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kela.
Abstract (Originalsprache)
Environmental impacts of medicines are increasingly recognised but rarely embedded in their pricing and reimbursement (P&R) and related assessments. This scoping review mapped how environmental aspects, including antimicrobial resistance (AMR) stewardship, are or could be considered in P&R of medicines and identified challenges for their implementation. Electronic searches from PubMed, Scopus, Web of Science, Edilex, HeinOnline, Westlaw, Google Scholar and official agencies' websites were conducted. Eligible items covered developed country settings and described existing or proposed integration of environmental aspects into medicine pricing or reimbursement. Of 4476 publications, 21 were included. The publications were from 2013 to 2023, most of them addressing ecotoxicological and climate impacts. Six types of means to embed environmental aspects into P&R were identified: health technology assessment (HTA) integration, reimbursement criteria, pricing criteria, environmental classification, regulation and delinkage models. Most proposals were conceptual, whereas implemented or piloted examples focused on AMR‐oriented means. Reported challenges for implementation included challenges regarding data availability, comparability and verification; valuation and methodological integration; incentive design and cost distribution; and equity and political feasibility. Environmental aspects are not yet routine in medicine P&R assessments due to a lack of standardised, verifiable product‐level data, appraisal methods and equity‐sensitive policy design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
- Law School, Faculty of Social Sciences and Business Studies, University of Eastern Finland, Kuopio, Finland.
ORCID-Profile: Lasse Alajärvi, Mirella Miettinen
Förderung
- Kela
Zitieren
APA
Alajärvi, L., Miettinen, M., & Timonen, J. (2026). Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review. Basic & Clinical Pharmacology & Toxicology, 138(6). https://doi.org/10.1111/bcpt.70243
Vancouver
Alajärvi L, Miettinen M, Timonen J. Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review. Basic & Clinical Pharmacology & Toxicology. 2026;138(6). doi:10.1111/bcpt.70243
BibTeX
@article{Alajrvi2026,
author = {Alajärvi, Lasse and Miettinen, Mirella and Timonen, Johanna},
title = {Environmental Aspects in Price and Reimbursement Decisions of Medicines—A Scoping Review},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {138},
number = {6},
doi = {10.1111/bcpt.70243}
}
EUVIMED